All studies have shown that PCSK9 mAbs (evolocumab or alirocumab) with or without statin therapy significantly reduce LDLc in patients with hypercholesterolemia and heterozygous familial hypercholesterolemia (31, 32, 49, 70). This evidence concerns the gene PCSK9 and familial hypercholesterolemia.